Skip to main content

Douglas Tremblay, MD

Douglas Tremblay, MD
Conference Coverage
01/03/2024
At the ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.
At the ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.
At the ASH Annual Meeting,...
01/03/2024
Oncology